NeuBase to participate in the 6th annual Chardin Genetic Medicine Conference

Pittsburgh And the Cambridge, Massachusetts.And the September 22 2022 (Globe Newswire) – NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or “the Company”), a biotech platform company Drugging the Genome™ to treat disease at the most basic level using a new class of micro-genetic drugs, announced today that company management will be participating in person for a fireside chat on its sixth anniversary. for Chardin Genetic Medicines Conference trapped in New York City on me 3-4 October 2022.

Offer details are as follows:
Date: Monday October 3
time: 09:009:25 a.m. ET
appearance: fireplace chat

An audio replay of the webcast will be available after the presentation for 90 days. To access the replay, please click here. Please contact your Chardan representative to schedule a one-on-one meeting with NeuBase management during the conference.

Read:Radiologist examines AI’s potential to transform medical imaging

Around NeuBase Treatments
NeuBase is accelerating the genetic revolution by developing a new class of precision gene drugs that utilize Genome Medicine™. The company’s treatments are built on a proprietary platform called PATrOL™ comprising a new anti-allergic nucleic acid peptide oligonucleobase technology combined with a new delivery shuttle that overcomes many obstacles to the involvement of selective mutagenesis, repeat dosing, and systemic delivery of gene drugs. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular disorders and tumors, NeuBase is committed to redefining medicine for millions of patients with common and rare conditions, who currently have limited or no treatment options. To learn more, visit

NeuBase investor contact: Daniel FerryGeneral Director
LifeSci . Consultantsy
[email protected]
OP: (617) 430-7576

NeuBase Media contact:Jessica YinglingPh.D.
Little Dog Communications Inc.
[email protected]
OP: (858) 344-8091

Read:Raising awareness of cardiovascular disease on this week’s Medical Monday

basic logo

source: NeuBase Therapeutics, Inc.

2022 GlobeNewswire, Inc. , Source press releases

Previous post
The strange and wonderful nature of British forests including Phallus “Stinkhorn” | UK news
Next post
Emma Raducano is in the Korea Open semi-finals and is looking forward to her best